[go: up one dir, main page]

WO1996011562A3 - Gene humain de controle et gene pour l'arn antisens de ce dernier - Google Patents

Gene humain de controle et gene pour l'arn antisens de ce dernier Download PDF

Info

Publication number
WO1996011562A3
WO1996011562A3 PCT/US1995/012445 US9512445W WO9611562A3 WO 1996011562 A3 WO1996011562 A3 WO 1996011562A3 US 9512445 W US9512445 W US 9512445W WO 9611562 A3 WO9611562 A3 WO 9611562A3
Authority
WO
WIPO (PCT)
Prior art keywords
gene
rap
antisense rna
human
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1995/012445
Other languages
English (en)
Other versions
WO1996011562A2 (fr
Inventor
Dan Canaani
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ramot at Tel Aviv University Ltd
Original Assignee
Ramot at Tel Aviv University Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ramot at Tel Aviv University Ltd filed Critical Ramot at Tel Aviv University Ltd
Priority to US08/817,436 priority Critical patent/US5882880A/en
Priority to AU37306/95A priority patent/AU3730695A/en
Publication of WO1996011562A2 publication Critical patent/WO1996011562A2/fr
Publication of WO1996011562A3 publication Critical patent/WO1996011562A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4738—Cell cycle regulated proteins, e.g. cyclin, CDC, INK-CCR
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

L'invention concerne un gène de contrôle (RAP-1) humain de protection contre les rayonnements et la protéine RAP-1 codée par le gène. On pense que le gène RAP-1 est impliqué dans la régulation de la progression du cycle cellulaire et/ou de la mort cellulaire programmée (apoptose). L'invention concerne également un ARN antisens humain qui peut se lier à l'ARNm de la protéine ARP-1 humaine, ainsi que l'ADN à partir duquel l'ARN antisens est transcrit. En outre, un procédé pour isoler des gènes de contrôle de l'endommagement de l'ADN est décrit. L'invention traite également de l'utilisation de séquences d'ADN et d'ARN et de la protéine selon l'invention pour la détection précoce, la prévention et/ou le traitement du cancer, du SIDA et d'autres maladies.
PCT/US1995/012445 1994-10-11 1995-10-11 Gene humain de controle et gene pour l'arn antisens de ce dernier Ceased WO1996011562A2 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US08/817,436 US5882880A (en) 1994-10-11 1995-10-11 Human checkpoint gene and gene for antisense RNA thereof
AU37306/95A AU3730695A (en) 1994-10-11 1995-10-11 Human checkpoint gene and gene for antisense RNA thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IL111238 1994-10-11
IL11123894A IL111238A (en) 1994-10-11 1994-10-11 Human checkpoint gene and gene for antisense rna thereof

Publications (2)

Publication Number Publication Date
WO1996011562A2 WO1996011562A2 (fr) 1996-04-25
WO1996011562A3 true WO1996011562A3 (fr) 1996-10-24

Family

ID=11066634

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1995/012445 Ceased WO1996011562A2 (fr) 1994-10-11 1995-10-11 Gene humain de controle et gene pour l'arn antisens de ce dernier

Country Status (3)

Country Link
AU (1) AU3730695A (fr)
IL (1) IL111238A (fr)
WO (1) WO1996011562A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5882880A (en) * 1994-10-11 1999-03-16 Ramot University Authority For Applied And Industrial Development Ltd. Human checkpoint gene and gene for antisense RNA thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993023571A1 (fr) * 1992-05-12 1993-11-25 Fred Hutchinson Cancer Research Center Genes points de controle du cycle cellulaire humain

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993023571A1 (fr) * 1992-05-12 1993-11-25 Fred Hutchinson Cancer Research Center Genes points de controle du cycle cellulaire humain

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DATABASE EMBL "yr12d06.r1 Soares fetal liver spleen 1NFLS Homo sapiens cDNA clone IMAGE:205067 5', mRNA sequence.", XP002005781 *
JEGGO, P. A. ET AL: "Cloning human DNA repair genes", INT. J. RADIAT. BIOL. (1994), 66(5), 573-7 CODEN: IJRBE7;ISSN: 0955-3002, 1994, XP002005780 *
KUERBITZ, STEVEN J. ET AL: "Wild-type p53 is a cell cycle checkpoint determinant following irradiation", PROC. NATL. ACAD. SCI. U. S. A. (1992), 89(16), 7491-5 CODEN: PNASA6;ISSN: 0027-8424, 1992, XP002005779 *

Also Published As

Publication number Publication date
WO1996011562A2 (fr) 1996-04-25
AU3730695A (en) 1996-05-06
IL111238A0 (en) 1994-12-29
IL111238A (en) 2003-05-29

Similar Documents

Publication Publication Date Title
WO1993001286A3 (fr) Therapie localisee utilisant des oligonucleotides
HUP0302332A3 (en) Gene detection method for improving the likelihood of an effective response to an erbb antagoist cancer therapy
WO2001068912A3 (fr) Diagnostic d'affections associees a des genes suppresseurs de tumeurs et a des oncogenes
WO2001077375A3 (fr) Diagnostic de maladies associees a la regulation genetique
WO2002002809A3 (fr) Diagnostic de troubles du comportement, de troubles neurologiques et de cancers
HU9501963D0 (en) 7-deazapurine modified oligonucleotides
WO2002102981A3 (fr) Procedes therapeutiques et prophylactiques a base de sir2$g(a)
WO2002074992A3 (fr) Gene humain implique dans l'accident vasculaire cerebral
DK1053313T3 (da) Optimerede antisense oligonucleotider komplementære til DNA methyltransferase-sekvenser
WO2005059108A3 (fr) Profils d'expression geniques et procedes d'utilisation
AU2003225281A8 (en) Materials and methods for prevention and treatment of rna viral diseases
WO2001032832A3 (fr) Modulation antisens de l'expression de la nucleoline
AU2003213054A8 (en) Rna interference mediated inhibition of polycomb group protein ezh2 gene expression using short interfering nucleic acid (sina)
WO1997022695A3 (fr) Sequences nucleotidiques, proteines, medicaments et agents diagnostiques utiles dans le traitement du cancer
WO2003101386A3 (fr) Suppresseur kinase de l'inactivation de ras pour traiter la tumorigenese induite par ras
DE69638166D1 (de) Integrin-gekoppelte kinase, ihre hemmstoffe und deren gebrauch für verfahren zur therapeutischen behandlung; gentherapie und bereitstellung von hemmstoffen, die als pseudosubstrate wirken
WO1996011562A3 (fr) Gene humain de controle et gene pour l'arn antisens de ce dernier
WO2005056756A3 (fr) Suppresseur de kinase d'inactivation de ras destine a la therapie de tumorigeneses induites par ras
WO1996039501A3 (fr) Oligonucleotides specifiques contre le papillomavirus humain
WO2004096826A3 (fr) Procede pour l'inhibition selective du gene humain n-myc dans les tumeurs exprimant n-myc au moyen de proteines pna antisens et antigeniques
AU6795201A (en) Nucleic acid sequences and methods for the modification of plant gene expression
EP1015630A4 (fr) Compositions et procedes permettant d'inhiber l'infection a virus de l'immunodeficience humaine par retro-regulation des genes cellulaires humains
WO2004046327A3 (fr) Oliogonucleotides inhibiteurs diriges sur bcl-2
WO2002008456A8 (fr) Procede d'identification de cellules tumorales metastatiques
ATE391777T1 (de) Verwendung von prohibitin-rns in krebsbehandlung

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU JP KE KG KP KR KZ LK LR LT LU LV MD MG MN MW MX NO NZ PL PT RO RU SD SE SI SK TJ TT UA US UZ VN

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): KE MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 08817436

Country of ref document: US

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA